Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key
roles in the initiation and regulation of innate and adaptive immune responses. As such …

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …

Intratumoral immunotherapy is an emerging modality for the treatment of solid tumors. Toll-
like receptor (TLR) agonists have shown promise for eliciting immune responses, but …

Immune-based therapies such as immune checkpoint inhibitors have revolutionized the
systemic treatment of various cancer types. The therapeutic application of monoclonal …

Tumour-associated macrophages are abundant in many cancers, and often display an
immune-suppressive M2-like phenotype that fosters tumour growth and promotes resistance …

Established evidence demonstrates that tumor-infiltrating myeloid cells promote rather than
stop-cancer progression. Tumor-associated macrophages (TAMs) are abundantly present at …

Background/Aim. Toll‐like receptors (TLRs) are pivotal biomolecules in the immune system.
Today, we are all aware of the importance of TLRs in bridging innate and adaptive immune …

Tumor immunotherapy has shown considerable therapeutic potential in the past few years,
but the clinical response rate of immunotherapy is less than 20%. Encountering the high …

Vaccines comprising innovative adjuvants are rapidly reaching advanced translational
stages, such as the authorized nanotechnology adjuvants in mRNA vaccines against COVID …

Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …